Trend
DailyDowntrend (starting)
4 hourSymmetric Triangle
1 hourExpanding
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $19.40
Key levels
Resistance$2.01
Resistance$1.83
Support$1.57
Support$1.36
Latest news & SEC filings
No headlines in the last 90 days.
Tenax Therapeutics is a clinical-stage drug developer working on treatments for heart and lung conditions. Its main candidate is an oral form of levosimendan, which is in late-stage testing for a type of pulmonary high blood pressure that occurs alongside a form of heart failure. A second candidate, imatinib, is not currently being advanced. The company is based in the United States and uses outside manufacturers and research organizations.
Based on the company's 10-K filed Mar 10, 2026.
Nasdaq · Healthcare
SEPT Low Target
$4.00
SEPT Mid Target
$5.00
SEPT High Target
$5.00
Analyst Consensus
$5.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TENX.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$5.21
12
Moat Score
NONE
1/9
Piotroski Score
0.5
Altman Z-Score
Insider Signal
BUYING
10 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% owner | Buy | 331,979 | $551K | Oct 21, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 254,342 | $406K | Oct 20, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 336,528 | $507K | Oct 19, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 900,000 | $1.6M | Sep 3, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 187,704 | $338K | Sep 2, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 179,058 | $322K | Sep 1, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 403,571 | $723K | Aug 31, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 107,374 | $188K | Aug 24, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 716,369 | $1.3M | Aug 21, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 202,124 | $360K | Aug 20, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-16.52%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for TENX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:45:18 | $1.64 | 3,000 | $$5K | BUY |
| 24:44:47 | $1.62 | 1,000 | $$2K | SELL |
| 24:44:47 | $1.62 | 1,000 | $$2K | SELL |
| 24:22:05 | $1.64 | 1,000 | $$2K | BUY |
| 20:59:49 | $1.60 | 3,616 | $$6K | SELL |
5 dark pool trades shown · $$16K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for TENAX THERAPEUTICS, INC. (TENX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TENAX THERAPEUTICS, INC. (TENX) is at $1.61, down 4.73% (-$0.08) at the Nov 12, 2026 close.
The average analyst price target for TENX is $5.00, ranging from $4 to $5, based on 3 analysts. Latest: Evercore ISI Group downgrade on Aug 11, 2026.
Analyst ratings for TENX: 0 Buy, 7 Hold, 5 Sell — consensus Hold.
TENX last reported on Jul 31, 2026: EPS -$0.35 vs -$0.38 expected — a beat of 8.2%.
TENX does not currently pay a dividend.
Support: $1.57, $1.36. Resistance: $1.83, $2.01, $2.22.
Insider activity: BUYING, 10 buys and 0 sells in the last 90 days.